Henry Schein (NASDAQ:HSIC) Upgraded by Wall Street Zen to “Strong-Buy” Rating

Henry Schein (NASDAQ:HSIC) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

A number of other analysts have also recently issued reports on the company. Morgan Stanley increased their target price on Henry Schein from $58.00 to $61.00 and gave the stock an “underweight” rating in a research note on Wednesday. Mizuho increased their price objective on shares of Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research report on Wednesday. UBS Group raised their price objective on shares of Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a report on Wednesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Finally, Robert W. Baird set a $100.00 target price on Henry Schein and gave the stock an “outperform” rating in a report on Monday. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Henry Schein currently has an average rating of “Hold” and an average target price of $85.58.

Henry Schein Price Performance

HSIC opened at $82.39 on Friday. The stock has a market cap of $9.45 billion, a P/E ratio of 25.20, a P/E/G ratio of 2.41 and a beta of 0.88. Henry Schein has a 12 month low of $60.56 and a 12 month high of $89.29. The company has a quick ratio of 0.79, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. The company has a fifty day simple moving average of $77.85 and a 200 day simple moving average of $72.15.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The firm had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same period in the previous year, the firm earned $1.19 earnings per share. The company’s revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, research analysts expect that Henry Schein will post 4.74 EPS for the current year.

Insider Activity at Henry Schein

In other Henry Schein news, CEO Stanley M. Bergman sold 38,346 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $81.01, for a total value of $3,106,409.46. Following the transaction, the chief executive officer owned 427,615 shares of the company’s stock, valued at $34,641,091.15. This represents a 8.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.08% of the stock is currently owned by company insiders.

Institutional Trading of Henry Schein

Institutional investors have recently added to or reduced their stakes in the stock. CYBER HORNET ETFs LLC acquired a new position in Henry Schein during the 2nd quarter worth $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein in the second quarter valued at approximately $27,000. Flagship Harbor Advisors LLC purchased a new position in Henry Schein in the fourth quarter worth approximately $30,000. Federated Hermes Inc. acquired a new position in Henry Schein during the 4th quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Henry Schein in the 4th quarter valued at approximately $37,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein News Roundup

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Reported quarterly results topped expectations (better EPS and revenue growth), which reinforces momentum in the stable dental market and was a primary driver for the stock rise. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Robert W. Baird upgraded HSIC, reflecting increased analyst confidence in growth/valuation after results. Upgrades can support further upside as they attract buy-side attention. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird
• Positive Sentiment: Leerink Partners published a bullish note forecasting strong price appreciation, adding to analyst-driven buying pressure. Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Positive Sentiment: Market reaction to the beat pushed HSIC to a new 12‑month high, signaling momentum traders and momentum-based funds may add exposure. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: A Yahoo/Finance piece notes analysts are re‑assessing HSIC’s growth profile and valuation — useful context but not an immediate directional catalyst. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Neutral Sentiment: Short‑interest data shows an anomalous report (0 shares / NaN change), which appears to be a reporting/data error and is unlikely to meaningfully affect near‑term trading.
• Negative Sentiment: CEO Stanley M. Bergman sold sizable blocks of stock on Feb. 26–27 (combined sale proceeds ~ $4.0M+), which can be perceived negatively by some investors as profit‑taking or reduced insider conviction. SEC filing: Insider sale filing

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.